Skip to main content
SpringerLink
Log in

Juvenile Dermatomyositis

Recognition and Treatment

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Juvenile dermatomyositis (JDM) is a multisystem disease characterized by acute and chronic lymphocytic inflammation of the skeletal muscle and skin. The disease is marked early in its course by the presence of a vasculopathy or vasculitis, and later by the development of calcinosis. Research has focused on the epidemiology, etiology, and pathogenesis of the disease with, until more recently, limited therapeutic interventions.

This article highlights treatment regimens, both traditional and more recent interventions. Traditional treatment for JDM includes high dose corticosteroid treatment with additional agents used in resistant disease or children with unwarranted adverse effects. Traditional therapy begins with daily oral corticosteroids, with intravenous corticosteroids utilized in severe disease; however, recent data suggests that short-term use of intravenous cortcosteroids will allow a short-term improvement in strength, with no long-term change in outcome. More recent investigations suggest that early intervention with additional immunomodulatory agents will allow for a faster recovery, with less medication and disease sequelae.

Use of methotrexate as an agent early in the disease course is becoming common place. Methotrexate, in conjunction with oral corticosteroids, allows a rapid improvement in symptoms, and allows for a more rapid reduction in corticosteroid dose. Methotrexate is considered as a steroid sparing agent, whether oral or intravenous corticosteroids are used. Additional immunomodulatory agents include the use of cyclosporine with or without methotrexate. Intravenous immunoglobulin has been reported to have benefit in resistant disease.

There are exciting new agents which have great potential in treating JDM. Many of these agents are termed biologics and are being tested in adult myositis and juvenile arthritis. These include tumor necrosis factor (TNF)-α inhibitors, such as a chimeric monoclonal antibody to TNF-α, and a recombinant soluble human TNF receptor (p75)-Fc fusion protein. Many other new biological agents are also being tested in myositis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Simmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34(8): 732–6

    Article  Google Scholar 

  2. Cawkwell GM. Inflammatory myositis in children, including differential diagnosis. Curr Opin Rheumatol 2000; 12: 430–4

    Article  PubMed  CAS  Google Scholar 

  3. Rider LJ, Miller SW. Classification and treatment of juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 23: 619–55

    Article  PubMed  CAS  Google Scholar 

  4. Reed AM, Sterling J. The HLA-DQA1*0501 allele in JDMS is seen in multiple racial groups. Hum Immunol 1995; 44: 131–5

    Article  PubMed  CAS  Google Scholar 

  5. Pachman LM. Juvenile dermatomyositis: pathophysiology and disease expression. Pediatr Clin North Am 1995; 42: 1071–98

    PubMed  CAS  Google Scholar 

  6. Engel AG, Arahata KM. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some disease, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17: 704–21

    Article  PubMed  CAS  Google Scholar 

  7. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 343–56

    Article  PubMed  CAS  Google Scholar 

  8. Elkington JR, Hunt AD, Godfrey L, et al. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy. JAMA 1949; 141: 1273–8

    Article  Google Scholar 

  9. Wedgewood RJP, Cook CD, Cohen J. Dermatomyositis: report of 26 cases in children with a discussion of endocrine therapy in 13. J Pediatr 1953; 12: 447–66

    Google Scholar 

  10. Carlisle JW, Good RA. Dermatomyositis in childhood. Lancet 1959; 79: 266–73

    CAS  Google Scholar 

  11. Romicka AM. Use of intravenous mega doses of methylprednisolone for treatment of dermatomyositis in children [in Polish]. Pediatr Pol 1995; 70: 243–8

    PubMed  CAS  Google Scholar 

  12. Lang B, Dooley J. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. J Pediatr 1996; 128(3): 429–32

    Article  PubMed  CAS  Google Scholar 

  13. Huang JL. Long term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. Clin Exp Rheumatol 1999; 17(5): 621–4

    PubMed  CAS  Google Scholar 

  14. Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30(3): 323–34

    Article  Google Scholar 

  15. Matsubara S, Sawa Y, Takamori M, et al. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies [letter]. J Neurol Neurosurg Psychiatry 1994; 57(8): 1008

    Article  PubMed  CAS  Google Scholar 

  16. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood. J Rheumatol 1994; 21(11): 2171–2

    Google Scholar 

  17. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 138–41

    Article  PubMed  CAS  Google Scholar 

  18. Miller LC, Sisson BA, Tucker LB, et al. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 1143–9

    Article  PubMed  CAS  Google Scholar 

  19. Adams EM, Plotz PH. The treatment of myositis: how to approach resistant disease. Rheum Dis Clin North Am 1995; 21: 179–202

    PubMed  CAS  Google Scholar 

  20. Henricksson KG, Lindvall B. Polymyositis and dermatomyositis: diagnosis, treatment, and prognosis. Prog Neurobiol 1990; 35: 1–193

    Article  Google Scholar 

  21. Zeller V, Cohen P, Prieur AM, et al. Cyclosporin a therapy in refractory juvenile dermatomyositis: experience and long term follow-up of 6 cases. J Rheumatol 1996; 23: 1424–7

    PubMed  CAS  Google Scholar 

  22. Sanchez RJ, Castilo-Palma MJ, Ocana MC, et al. The efficacy of cyclosporin in the treatment of myositis. Rev Clin Esp 1995; 195: 449–54

    Google Scholar 

  23. Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporin and high-dose intravenous immunoglobulin. South Med J 1995; 88: 866–70

    Article  PubMed  CAS  Google Scholar 

  24. Dantzig P. Juvenile dermatomyositis treated with cyclosporin. J Am Acad Dermatol 1990; 22: 310–1

    Article  PubMed  CAS  Google Scholar 

  25. Giardin E, Dayer JM, Paunier L. Cyclosporin for juvenile dermatomyositis. J Pediatr 1988; 12: 165–6

    Google Scholar 

  26. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; I: 1063–6

    Article  Google Scholar 

  27. Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993; 11: 203–8

    PubMed  CAS  Google Scholar 

  28. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436–43

    PubMed  CAS  Google Scholar 

  29. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 445–6

    Article  Google Scholar 

  30. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498–503

    PubMed  CAS  Google Scholar 

  31. Sansome A, Dubowitz V. Intravenous immunoglobulin juvenile dermatomyositis: four-year review of nine cases. Arch Dis Child 1995; 72: 25–8

    Article  PubMed  CAS  Google Scholar 

  32. Roifman CM. Use of intravenous immunoglobulin in the therapy of children with rheumatologic diseases. J Clin Immunol 1995; 15(6 Suppl.): S42–51

    Article  Google Scholar 

  33. Lang BA, Laxer RM, Murray G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169–72

    Article  PubMed  CAS  Google Scholar 

  34. Colet E, Dalac S, Maerens B, et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 1994; 130: 231–4

    Article  Google Scholar 

  35. Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol 1992; 33: 94–7

    CAS  Google Scholar 

  36. Tsai MJ, Lai CC, Lin SC, et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Chung-Hua Min Kuo 1997; 38: 111–5

    CAS  Google Scholar 

  37. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104Suppl. 1: 3–9

    PubMed  CAS  Google Scholar 

  38. Vedanarayanan V, Subramony SH, Ray LI, et al. Treatment of juvenile dermatomyositis with high-dose intravenous gammaglobulin. Pediatr Neurol 1995; 13: 336–9

    Article  PubMed  CAS  Google Scholar 

  39. Miller JJ. Late progression in dermatomyositis in childhood. J Pediatr 1973; 83: 543–8

    Article  PubMed  Google Scholar 

  40. Pachman LM, Hayford JR, Sinacore J, et al. New onset juvenile dermatomyositis (JDMS): a clinical description [abstract]. Arthritis Rheum 1992; 35: 88

    Google Scholar 

  41. McGhee B, McCombs JR, Boyle G, et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. Transplantation 1997; 64(6): 941–2

    Article  PubMed  CAS  Google Scholar 

  42. Modesto C, Boronat M, Marsal S, et al. FK-506 in the treatment of unresponsive juvenile dermatomyositis. Ann Rheum Dis 2000; 59: 727–9

    Article  Google Scholar 

  43. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy: experience with 35 patients. Arch Neurol 1981; 38: 544–52

    Article  PubMed  CAS  Google Scholar 

  44. Anderson L, Ziter FA. Plasmapheresis via central catheter in dermatomyositis: a new method for selected pediatric patients. J Pediatr 1981; 98: 240–1

    Article  PubMed  CAS  Google Scholar 

  45. Miller ML, Mendez E, Klein-Gitelman M, et al. Experience with etanercept in chronic juvenile dermatomyositis (JDM): preliminary results [abstract]. Arthritis Rheum 2000; 1883: S380

    Google Scholar 

  46. Wulffraat NM, Sanders LAM, Kuis W. Autologous hemopoetic stem cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000; 2: 316–23

    Article  PubMed  CAS  Google Scholar 

  47. Clarke AE, Bloh DA, Medsger Jr TA, et al. A longitudinal study of functional disability in a national quarter of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995; 38: 1218–24

    Article  PubMed  CAS  Google Scholar 

  48. Reed AM, Haugen MS, Pachman LM, et al. Osteopenia in children with chronic rheumatic diseases correlates with disease activity. J Pediatr 1993; 122: 693–6

    Article  PubMed  CAS  Google Scholar 

  49. Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable responses to aluminum hydroxide therapy. Arch Dermatol 1988; 124: 1721–2

    Article  PubMed  CAS  Google Scholar 

  50. Nassim JR, Connolly CK. Treatment of calcinosis universalis with aluminum hydroxide. Arch Dis Child 1970; 45: 18–121

    Article  Google Scholar 

  51. Palmieri GM, Sebes JI, Aelion JA, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum 1995; 38: 1646–54

    Article  PubMed  CAS  Google Scholar 

  52. Oliveri MB, Palermo R, Mautalen C, et al. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996; 3: 2152–5

    Google Scholar 

  53. Falcini F, Trapani S, Ermini M, et al. Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 1996; 58: 166–9

    PubMed  CAS  Google Scholar 

  54. Ichiki Y, Akiyama T, Shimozawa N, et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis and succesful treatment with diltiazem. Br J Dermatol 2001; 144(4): 894–7

    Article  PubMed  CAS  Google Scholar 

  55. Nakagawa T, Tkaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol 1993; 20(9): 558–60

    PubMed  CAS  Google Scholar 

  56. Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol 1998; 25(11): 716–20

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the clerical assistance of Elizabeth Timm.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA

    Ann M. Reed (Chief of Pediatric Rheumatology and Associate Professor of Pediatrics)

  2. Duke University Medical Center and the University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA

    Maricarmen Lopez

Authors
  1. Ann M. Reed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maricarmen Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann M. Reed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reed, A.M., Lopez, M. Juvenile Dermatomyositis. Pediatr-Drugs 4, 315–321 (2002). https://doi.org/10.2165/00128072-200204050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204050-00004

Keywords

Search

Navigation